ArticleJournal of immunology (Baltimore, Md. : 1950)2019
Widespread Tau-Specific CD4 T Cell Reactivity in the General Population.
Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04239079 (Autoimmune Features of Neurodegenerative Disorders), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Autoimmune Features of Neurodegenerative Disorders
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.Translational neurodegeneration · 2025Review
- Emerging roles for innate and adaptive immunity in tauopathies.Cell reports · 2025Review
- Altered T-cell reactivity in the early stages of Alzheimer's disease.Brain : a journal of neurology · 2025Article
- Identification of UBE2N as a biomarker of Alzheimer's disease by combining WGCNA with machine learning algorithms.Scientific reports · 2025Article
- CD4Cells · 2024Review
- PINK1 is a target of T cell responses in Parkinson's disease.bioRxiv : the preprint server for biology · 2024Article
- Antigen-specific and cross-reactive T cells in protection and disease.Immunological reviews · 2023Review
- T cell aging and Alzheimer's disease.Frontiers in immunology · 2023Review
- Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B.Circulation research · 2022Article
- CD11bJournal of immunology (Baltimore, Md. : 1950) · 2022Article
- Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures.NPJ Parkinson's disease · 2022Article
- Emerging Roles of T Helper Cells in Non-Infectious Neuroinflammation: Savior or Sinner.Frontiers in immunology · 2022Review
- T cells, α-synuclein and Parkinson disease.Handbook of clinical neurology · 2022Review
- Insights into T-cell dysfunction in Alzheimer's disease.Aging cell · 2021Review
- Cascading from SARS-CoV-2 to Parkinson's Disease through Protein-Protein Interactions.Viruses · 2021Article
- The role of immune-mediated alterations and disorders in ALS disease.Human immunology · 2021Review
- Inflammation in Experimental Models of α-Synucleinopathies.Movement disorders : official journal of the Movement Disorder Society · 2021Review
- T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls.Frontiers in neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging. Although not known to produce autoimmune responses, we hypothesized that the appearance of aggregated tau and p-tau with disease could activate the immune system. We thus compared T cell responses to tau and p-tau-derived peptides between PD patients, age-matched healthy controls, and young healthy controls (<35 y old; who are less likely to have high levels of tau aggregates). All groups exhibited CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.